KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.Acta Derm VenereolPMID 42272192PMC132537602026-Jun-100.98未发现恶性肿瘤人群证据。已完成
IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.Neurology已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。PMID 42096672PMC131652872026-Jun-090.98未发现恶性肿瘤人群证据。无 KM 图
Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42100960PMC131567982026-Jun-090.98未发现恶性肿瘤人群证据。无 KM 图
[Efficacy and safety of combining olorigliflozin with metformin in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy].Zhonghua Yi Xue Za ZhiPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42252239无 PMCID2026-Jun-090.98未发现恶性肿瘤人群证据。无 KM 图
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.J Crohns Colitis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 other;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图;另有 1 张未列出。PMID 42309525PMC132751312026-Jun-070.98未发现恶性肿瘤人群证据。无 KM 图
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42119587无 PMCID2026-Jun-060.98未发现恶性肿瘤人群证据。无 KM 图
Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.OncologistPMID 42179186PMC132578602026-Jun-060.90The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original results, but the primary and key secondary endpoints are proportion-based (spleen volume reduction, symptom score reduction) and are not time-to-event outcomes. No time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) is reported or mentioned.已完成
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42214397无 PMCID2026-Jun-060.98未发现恶性肿瘤人群证据。无 KM 图
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.BloodPMID 41758929PMC132776512026-Jun-040.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.J Pharmacokinet Pharmacodyn已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。PMID 42243460PMC132368352026-Jun-040.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41967349无 PMCID2026-Jun-030.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42019226无 PMCID2026-Jun-030.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).J Neurol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图。PMID 42234197PMC132339762026-Jun-030.98未发现恶性肿瘤人群证据。无 KM 图
Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42096239PMC131540352026-Jun-020.98未发现恶性肿瘤人群证据。无 KM 图
Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42099212PMC131567992026-Jun-020.98未发现恶性肿瘤人群证据。无 KM 图
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer.J Natl Cancer InstPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40880294无 PMCID2026-Jun-010.95The report focuses on long-term benign event rates and endometrial safety in a prevention trial, not the primary or key secondary time-to-event efficacy endpoint of the oncology trial.无 KM 图
Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.Int J Radiat Oncol Biol PhysPMID 41285272PMC130523782026-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.Diabetes Care疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:非 KM 图。PMID 41296499PMC131914232026-Jun-010.98未发现恶性肿瘤人群证据。无 KM 图
Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.Clin Cancer ResPMID 41504634PMC132235402026-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Effects of a structured exercise program on motivational outcomes in patients with colon cancer.J Natl Cancer Inst疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:AI 判定为 other;Figure 3.:非 KM 图;Figure 4.:非 KM 图。PMID 41609410PMC132473382026-Jun-010.90The study is a randomized, phase 3 oncology trial in human colon cancer patients. However, the reported intervention is a structured exercise program (non-drug), and the primary outcomes are motivational/social cognitive beliefs (not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.). No drug-containing intervention is described.无 KM 图
Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.Inflamm Bowel Dis已检查 6 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 1 张未列出。PMID 41655066PMC132331362026-Jun-010.98未发现恶性肿瘤人群证据。无 KM 图
Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41711624无 PMCID2026-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.Inflamm Bowel Dis已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图;Figure 4:研究设计图;Figure 5:AI 判定为 other;另有 2 张未列出。PMID 41777218PMC132331442026-Jun-010.98未发现恶性肿瘤人群证据。无 KM 图
Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial.JAMA PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41811299PMC129803592026-Jun-010.98未发现恶性肿瘤人群证据。无 KM 图
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.Clin Cancer ResPMID 41837753PMC132235492026-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Results of the Pediatric Guideline Adherence and Outcomes (PEGASUS) Program Versus Usual Care Pragmatic Randomized Controlled Trial in Severe Traumatic Brain Injury.Crit Care MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41891786无 PMCID2026-Jun-010.98未发现恶性肿瘤人群证据。无 KM 图
Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.JAMA Psychiatry已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:生活质量量表图。PMID 41920558PMC130447892026-Jun-010.98未发现恶性肿瘤人群证据。无 KM 图
Cerebral Oximetry in Extremely Preterm Infants: 2-Year Follow-Up of the SafeBoosC-III Randomized Clinical Trial.JAMA Pediatr疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure.:非 KM 图。PMID 42008246PMC130970322026-Jun-010.98未发现恶性肿瘤人群证据。无 KM 图
Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.JAMA Ophthalmol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:AI 判定为 other;Figure 3.:AI 判定为 other。PMID 42024409PMC131073092026-Jun-010.98未发现恶性肿瘤人群证据。无 KM 图
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.JAMA OncolPMID 42060297PMC131337232026-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.JAMA Netw OpenPMID 42295761PMC132702722026-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Comparing the Recurrence Patterns of Reduced-Margins vs. RTOG-Protocol in Adjuvant Chemoradiation of High-Grade Gliomas: A Multicenter, Open-Label, Randomized Controlled Trial.Asian Pac J Cancer Prev疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42345146无 PMCID2026-Jun-010.90The study is a Phase III randomized controlled trial with a primary time-to-event endpoint (PFS) for a human malignant neoplasm (high-grade glioma). However, the randomized intervention is a comparison of radiotherapy target volume margins (reduced-margin vs. standard RTOG-protocol), not a drug-containing intervention. The abstract does not describe a drug-containing arm as part of the randomized comparison; 'adjuvant chemoradiation' in the title likely refers to the overall treatment context, not the experimental variable being tested.无 KM 图
Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial.J Am Acad Child Adolesc PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40619095无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Whole Brain Radiotherapy Versus Stereotactic Radiosurgery in Breast Cancer Patients With Brain Metastases-A Phase 3 Open Label Randomized Study.Asia Pac J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40983872无 PMCID2026-Jun0.95Study meets all criteria except drug intervention. It is a Phase III randomized trial in human oncology with primary time-to-event endpoints (OS, PFS), but compares two radiotherapy techniques (WBRT vs SRS) without a drug-containing arm. The required drug intervention is not present.无 KM 图
Neonatal morbidity in early-onset fetal growth restriction with and without anticoagulant therapy.Pediatr ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41034645无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41073155无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41193271无 PMCID2026-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.Diabetologia入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41272211无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.Int J DermatolPMID 41272415PMC131615092026-Jun0.98未发现恶性肿瘤人群证据。已完成
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.J Eur Acad Dermatol Venereol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:森林图/亚组分析图。PMID 41297955PMC132062572026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Five-Grass-Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial.Allergy疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图。PMID 41444697PMC132562692026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.Arthritis RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41466456无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.Ann Surg OncolPMID 41535566PMC131791692026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41571045无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.J Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41580093无 PMCID2026-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial.Lancet Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::非 KM 图;Figure 4::森林图/亚组分析图。PMID 41619753PMC130404532026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41621752无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41642173无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study.J Eur Acad Dermatol Venereol已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:AI 判定为 flow diagram;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 multi panel km。PMID 41678327PMC132063642026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41687718无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图